Stability of human immunoglobulin(pH 4) for intravenous injection after process optimization
10.13200/j.cnki.cjb.004034
- VernacularTitle:静注人免疫球蛋白（pH 4）工艺优化后产品的稳定性
- Author:
CAO Jing
- Publication Type:Journal Article
- Keywords:
Human immunoglobulin(pH 4) for intravenous injection(IGIV);
Process optimization;
Immunoglobulin A(IgA);
Stability
- From:
Chinese Journal of Biologicals
2023;36(11):1319-1323
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the stability of human immunoglobulin(pH 4)for intravenous injection(IGIV)after process optimization.Methods A filter plate and B filter membrane were used to filter the protein components in different separation stages to reduce the residue of immunoglobulin A(IgA)in the product in multi-batch large-scale production. The finished product was examined for the physical properties(appearance,visible foreign body,insoluble particle examination and thermal stability test)and the chemical properties[protein content,purity,molecular size distribution,titers of antiHBs,diphtheria antibody,prokallikrein activator(PKA),anti-complement activity(ACA),anti-A and anti-B hemagglutinin,and IgA residue]. The accelerated and long-term stability tests were performed.Results There was no significant difference in the key quality indicators between IGIV batches produced by the optimized process and the normal process,while the IgA residue decreased significantly(t = 3. 992 and 11. 215 respectively,each P < 0. 05). In the accelerated stability and long-term stability tests,all the test results of IGIV after process optimization were qualified,which met the relevant regulations in the third part of Chinese Pharmacopoeia(2020 edition).Conclusion IGIV after process optimization can effectively reduce IgA residue with good stability,which is of great significance for blood product manufacturers to improve the quality of IGIV products.
